Європейський Союз - румунська - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imunosupresoare - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

venus pharma gmbh - germania - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice inhibitori de proteazom

Європейський Союз - румунська - EMA (European Medicines Agency)

accord healthcare s.l.u. - acetat de abirateron - prostate neoplasme - terapia endocrină - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Європейський Союз - румунська - EMA (European Medicines Agency)

mylan ireland limited - acetat de abirateron - prostate neoplasme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania, s.l. - spania - abirateronum - compr. film. - 500mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare

Європейський Союз - румунська - EMA (European Medicines Agency)

krka, d.d., novo mesto - acetat de abirateron - prostate neoplasme - terapia endocrină - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.